Discover the latest news from the Pulmonary Hypertension, including advocacy updates, research articles and event coverage.
Apply now to take part in PHA's Capitol Hill Day on Monday, March 9, 2026. Advocates will speak to legislators about the challenges of accessing supplemental oxygen and affordable, adequate health insurance coverage. No prior advocacy experience is needed.
Get involved | News
Tiffani Brown and Debbie Kittel, co-leaders of the Ohio State University Support Group, gathered 66 pulmonary hypertension patients, caregivers and health care providers for their inaugural Friendsgiving.
Support
PHA thanks everyone who invested in our mission on GivingTuesday. Your generosity helps provide support for people with pulmonary hypertension.
Pittsburgh Steelers kicker Chris Boswell is the latest NFL player to design PH-related cleats for the My Cause, My Cleats campaign.
During Stephanie Tsoi’s pediatric residency, she quickly realized how much researchers and clinicians still have to uncover about PH. “Caring for critically ill children … continues to inspire me to keep asking new questions and pursuing innovative research that can change outcomes,” says Tsoi, the recipient of PHA’s 2025 Early Career Mentored Scientist Award.
Diagnosis & treatment
The Pulmonary Hypertension Association accredited 11 new Pulmonary Hypertension Care Centers in 2025. There are now 107 PHA-accredited PH care centers throughout the United States.
Accredited care centers
Ralinepag met a primary goal to delay disease progression in a Phase 3 study, United Therapeutics announced. The study met several secondary goals, including six-minute walk distance.
Read morePulmovant has completed enrollment for its Phase 2 PHocus clinical trial to evaluate a once-daily inhaled treatment for PH-ILD. Mosliciguat helps widen blood vessels and could have anti-inflammatory and anti-fibrotic properties.
Read moreGossamer Bio’s Phase 3 seralutinib trial narrowly missed its primary endpoint goal to show improved six-minute walk distance at week 24, according to its news release. An unexpectedly large improvement in walk distance in the placebo group appeared in part to influence the outcome, Gossamer says. The company noted encouraging findings in key secondary goals, including reductions in NT-proBNP, improvements in clinical status and lower risk scores. The study also showed meaningful treatment effects in patients with intermediate and high-risk PH, Gossamer explains in a document for patients (pdf).
Read more
